Obeticholic Acid

目录号:S7660 别名: INT-747, 6-ECDCA, 6-Ethylchenodeoxycholic acid 中文名称:奥贝胆酸

仅限科研使用

Obeticholic Acid (INT-747, 6-ECDCA, 6-Ethylchenodeoxycholic acid)是一种有效的选择性farnesoid X receptor (FXR)兴奋剂,EC50为99 nM。Obeticholic Acid 可抑制自噬。Phase 3。

Obeticholic Acid Chemical Structure

CAS: 459789-99-2

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1203.93 现货
RMB 809.97 现货
RMB 2851.57 现货
RMB 8001.23 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Obeticholic Acid发表文献13篇:

质量管理及产品安全说明书

FXR抑制剂选择性比较

相关FXR产品

生物活性

产品描述 Obeticholic Acid (INT-747, 6-ECDCA, 6-Ethylchenodeoxycholic acid)是一种有效的选择性farnesoid X receptor (FXR)兴奋剂,EC50为99 nM。Obeticholic Acid 可抑制自噬。Phase 3。
靶点
FXR [1]
99 nM(EC50)
体外研究

在HuH7细胞中,Obeticholic Acid是一种有效的FXR激动剂,EC50 为85 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
insect cells MYDGeY5kfGmxbjDhd5NigQ>? MnTKNUBpeg>? NHHYVYtC\2:waYP0JIFkfGm4aYT5JIF1KHKnY3;tZolv[W62IHj1cYFvKEeVVD30ZYdo\WRiRmjSJIxq\2GwZDDibY5lcW6pIHTvcYFqdiBqMUmzJJRwKDR5MjDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbY51\XKjY4Tpc44hf2m2aDDibY91cW5ibHHi[Yxt\WRiU2LDMVEh[W[2ZYKgNUBpeiCkeTDIWHJHKGG|c3H5MEBGSzVyIE2gNE4xOSEQvF2u MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2OEiwOkc,OjlzNEi4NFY9N2F-
HEK293T NEPw[4JHfW6ldHnvckBie3OjeR?= Mm[zNlQhcHK| M{fyVWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gSnhTKGW6cILld5Nm\CCrbjDISWszQTOWIHPlcIx{KGG|c3Xzd4VlKGG|IFLTSXAheHKxbX;0[ZIh\HKrdnXuJINmdGy3bHHyJJRz[W6|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyIE2gNE4xPDJizszNMi=> NXLaUHlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFg5ODZpPkK5NVQ5QDB4PD;hQi=>
COS1 NV6yfZhQTnWwY4Tpc44h[XO|YYm= NXjHcYxuSWexbnnzeEBi[3Srdnn0fUBifCCIWGKg[ZhxemW|c3XkJIlvKEORU{GgZ4VtdHNiYomgZ4VtdC2kYYPl[EBjcW:udX3pcoV{[2WwY3WgZZN{[XluIFXDOVAhRSByLkC5PUDPxE1w M4D0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEG0PFcxLz5{MECxOFg4ODxxYU6=
HeLa MlHuSpVv[3Srb36gZZN{[Xl? M2nyR|I1KGi{cx?= NX;VcFYySWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBnfWyuIHzlcod1cCCIWGKg[ZhxemW|c3XkJIlvKEinTHGgZ4VtdHNiY3;0doFve2[nY4Tl[EB4cXSqIIDTS|UucHWvYX6gVnhTKGGodHXyJFI1KGi{czDifUBFfWGuLVfsc{BtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkG2JO69VS5? M3z0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO0NlI4Lz5{NUmzOFIzPzxxYU6=
HeLa M1XOXWZ2dmO2aX;uJIF{e2G7 NG\MNItC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGZZWiCneIDy[ZN{\WRiaX6gbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bz\WOncITvdkBi[3SrdnH0bY9vKGK7IFLTSXAheHKxbX;0[ZIu\HKrdnXuJIZqemWobImgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC5zNjFOwG0v MkO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUWwN|koRjJ3MkW1NFM6RC:jPh?=
insect cells NYDQfmhbTnWwY4Tpc44h[XO|YYm= NVjKPJJPOSCqch?= MkPrRYdwdmm|dDDhZ5Rqfmm2eTDheEBz\WOxbXLpcoFvfCCqdX3hckBIW1RvdHHn[4VlKE[[UjDMRmQhMDF7MzD0c{A1PzJicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCrboPlZ5Qh[2WubIOgZZN{\XO|ZXSgZZMhemWlcoXpeI1mdnRib3[gZolwfGmweXzheIVlKFOUQ{GgdIVxfGmmZTDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KEGucHjhd4Nz\WWwIHHzd4F6NCCHQ{WwJF0hOC5zODFOwG0v M2PLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkW5O|QzLz5{OUK1PVc1OjxxYU6=
COS1 MkLFSpVv[3Srb36gZZN{[Xl? NGXSe3Y2KGi{cx?= MW\B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIF\YVkBmgHC{ZYPz[YQhcW5iQ1;TNUBk\WyuczDh[pRmeiB3IHjyd{BjgSCFUlWt[JJqfmWwIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvOzZzIN88UU4> NF;GNY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OVYxOyd-MUe2PFU3ODN:L3G+
CHO MnvZSpVv[3Srb36gZZN{[Xl? NEDKTJg2KGi{cx?= NX7GUJN{SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVT1J3IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[W[2ZYKgOUBpenNiYomgR3JGNWS{aY\lckBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLke1OUDPxE1w NHjNO|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OVYxOyd-MUe2PFU3ODN:L3G+
HEK293 MnT6SpVv[3Srb36gZZN{[Xl? Ml7mNUBpeg>? MnnsRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUS3I2KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWuIHHmeIVzKDFiaIKgZpkhXFJvRmLFWEBie3OjeTygSWM2OCB;IECuPFQh|ryPLh?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ3OUe0Nkc,Ojl{NUm3OFI9N2F-
NCI-H716 M3Xqd2Z2dmO2aX;uJIF{e2G7 M3za[2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGdTPSC{ZXPldJRweiCneIDy[ZN{\WRiaX6gUmNKNUh5MU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY51emGlZXzseYxieiClQV3QJIxmfmWuIHL5JHRTNU[URWSgZZN{[XluIFXDOVAhRSB{MDFOwG0v M2XwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW5OVgxLz5{MUS1PVU5ODxxYU6=
HepG2 M2XFVmZ2dmO2aX;uJIF{e2G7 Mn7ENlAhfU1? NGTGfFVKdmS3Y4Tpc44hd2ZiRmjSMY1m\GmjdHXkJHNJWCCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNlAhfU1iYomgVnQuWEOU M2PVSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW5OVgxLz5{MUS1PVU5ODxxYU6=
HepG2 M3rmb2Z2dmO2aX;uJIF{e2G7 M320UVEhfU1? NU[1WlZ{UW6mdXP0bY9vKG:oIF\YVk1u\WSrYYTl[EBUUFBibWLORUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFEhfU1iYomgVnQuWEOU NIHNd2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1PVU5OCd-MkG0OVk2QDB:L3G+
HepG2 Mlr2SpVv[3Srb36gZZN{[Xl? NF3EfYkzOCC3TR?= M{jlemlv\HWldHnvckBw\iCIWGKtcYVlcWG2ZXSgRnNGWCCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNlAhfU1iYomgVnQuWEOU M3XoXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW5OVgxLz5{MUS1PVU5ODxxYU6=
HepG2 NWTGOVRjTnWwY4Tpc44h[XO|YYm= M3K4ZlIxKHWP NWjJbFVbUW6mdXP0bY9vKG:oIF\YVk1u\WSrYYTl[EBQe3SkZYThJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCB{MDD1UUBjgSCUVD3QR3I> NY[xN5NzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVk2QDBpPkKxOFU6PThyPD;hQi=>
HepG2 M33XW2Z2dmO2aX;uJIF{e2G7 MWmxJJVO MV;JcoR2[3Srb36gc4YhTliULX3l[IlifGWmIHTve44uemWpdXzheIlwdiCxZjDDfZA4STFibWLORUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFEhfU1iYomgVnQuWEOU Mn21QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NUm1PFAoRjJzNEW5OVgxRC:jPh?=
HepG2 M17ZdmZ2dmO2aX;uJIF{e2G7 M3fISFIxKHWP NY\XS5k2UW6mdXP0bY9vKG:oIF\YVk1u\WSrYYTl[EBld3ewLYLl[5Vt[XSrb36gc4YhS3myN1GxJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCB{MDD1UUBjgSCUVD3QR3I> M2fLdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW5OVgxLz5{MUS1PVU5ODxxYU6=
HepG2 M2HIPWZ2dmO2aX;uJIF{e2G7 MmLmNlAhfU1? NWDucFZISWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBHYFJiZYjwdoV{e2WmIHnuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IILlcoltdGFibIXjbYZmemG|ZTDhZ5Rqfmm2eTDheEAzOCC3TTDifUBtfWOrZnXyZZNmKGKjc3XkJJRz[W6|YXP0bZZifGmxbjDhd5NigQ>? NU\ldZY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVk2QDBpPkKxOFU6PThyPD;hQi=>
HepG2 MmS0SpVv[3Srb36gZZN{[Xl? M1viUlEhfU1? M4XsSmlv\HWldHnvckBw\iCIWGKtcYVlcWG2ZXSgRnNGWCCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNUB2VSCkeTDSWE1RS1J? M4fNdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW5OVgxLz5{MUS1PVU5ODxxYU6=
HepG2 MV7GeY5kfGmxbjDhd5NigQ>? NEX5ZW8yKHWP NXv3ZZk3UW6mdXP0bY9vKG:oIF\YVk1u\WSrYYTl[EBQe3SkZYThJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCBzIIXNJIJ6KFKWLWDDVi=> M2HGXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW5OVgxLz5{MUS1PVU5ODxxYU6=
HepG2 MX7GeY5kfGmxbjDhd5NigQ>? MXixNEB2VQ>? MmPJWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIF\YVkB1emGwc3\lZ5Rm\CCrbjDoeY1idiCKZYDHNkBk\WyuczDheEAyOCC3TTDifUBj\XSjLXfhcIFkfG:|aXThd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? MmThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEezNlUoRjJ2M{i3N|I2RC:jPh?=
HepG2 MWXGeY5kfGmxbjDhd5NigQ>? M3myPFExKHWP MoPMNVghcHK| M3\DWmFod26rc4SgZYN1cX[rdImgZZQhTliUIHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBQW1RvYXzwbIEhdVKQQTDlfJBz\XO|aX;uJIF1KDFyIIXNJIFnfGW{IEG4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN? M4O2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{i3N|I2Lz5{NEO4O|MzPTxxYU6=
GLUTag MoHRSpVv[3Srb36gZZN{[Xl? MoPxRYdwdmm|dDDhZ5Rqfmm2eTDheEBIWC2EQWKxJIlvKG2xdYPlJGdNXVSjZzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IHPBUXAhdGW4ZXy= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN6N{OyOUc,OjR|OEezNlU9N2F-
HepG2 MVrGeY5kfGmxbjDhd5NigQ>? NGrq[4QyOCC3TR?= MnvPNVghcHK| NYj2T5l2SWexbnnzeEBi[3Srdnn0fUBifCCIWGKgbY4hcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNidYDy[Yd2dGG2aX;uJI9nKFOKUDDtVm5CKGW6cILld5Nqd25iYYSgNVAhfU1iYX\0[ZIhOThiaILzJIJ6KFKWLWDDVkBidmGueYPpdy=> MkPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEezNlUoRjJ2M{i3N|I2RC:jPh?=
HepG2 NW\pUml{TnWwY4Tpc44h[XO|YYm= M2DxclExKHWP MmG4NVghcHK| M1jSSGFod26rc4SgZYN1cX[rdImgZZQhTliUIHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBDTVOSIH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VSCjZoTldkAyQCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nz Mn;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEezNlUoRjJ2M{i3N|I2RC:jPh?=
GLUTag MX3GeY5kfGmxbjDhd5NigQ>? MkfRRYdwdmm|dDDhZ5Rqfmm2eTDheEBIWC2EQWKxJIlvKG2xdYPlJGdNXVSjZzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBIVFBvMTDy[Yxm[XOn NIjMe2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO4O|MzPSd-MkSzPFc{OjV:L3G+
Assay
Methods Test Index PMID
Western blot XBP1s p-IRE1α 29377207
体内研究 在大鼠胆汁郁积模型中,Obeticholic Acid促进胆汁流动,并保护肝细胞免受LCA引起的急性坏死。[1] 在WD喂养的DBA 小鼠体内,Obeticholic Acid (p.o.)改善蛋白尿和肾脏结构的改变,并调节肾脏炎症和氧化应激。[2]在硫代乙酰胺(TAA)中毒的和胆小管结扎的(BDL)大鼠体内,Obeticholic Acid (30 mg/kg p.o.) 通过降低总IHVR,恢复FXR下游信号通路,并降低门静脉压力,而不产生有害的全身性低血压。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
  • Animal Models: 大鼠胆汁郁积模型
  • Dosages: 生理盐水
  • Administration: 使用 PE-50 聚乙烯管在右颈动脉进行注射

溶解度(25°C)

体外

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 420.63
化学式

C26H44O4

CAS号 459789-99-2
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02633956 Completed Drug: Obeticholic Acid|Drug: Atorvastatin|Drug: Placebo Nonalcoholic Steatohepatitis Intercept Pharmaceuticals December 4 2015 Phase 2
NCT02548351 Active not recruiting Drug: Obeticholic Acid|Drug: Placebo Non Alcoholic Steatohepatitis (NASH) Intercept Pharmaceuticals September 22 2015 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
What formulation can we use to dissolve Obeticholic Acid (Catalog No.S7660) for mice in vivo study?

回答:
You can use the vehicle of: 1% wt/vol methyl-cellulose as indicated in this paper, http://www.sciencedirect.com/science/article/pii/S0925443911000883 "daily oral gavage with 5 mg/kg/day INT-747 (6-ethyl-chenodeoxycholic acid, Obeticholic acid, Intercept Pharmaceuticals Inc, New York, NY) or vehicle (1% wt/vol methyl-cellulose) from 3 days prior to induction of colitis"